⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNKD News
Mannkind Corporation
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
globenewswire.com
MNKD
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
globenewswire.com
MNKD
Form 8-K
sec.gov
MNKD
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
globenewswire.com
MNKD
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
globenewswire.com
MNKD
Form 8-K
sec.gov
MNKD
MannKind to Present at Jefferies Global Healthcare Conference
globenewswire.com
MNKD
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
globenewswire.com
MNKD
Form 8-K
sec.gov
MNKD
The $59B Quiet Shift Reshaping How Patients Access Care
prnewswire.com
NVO
DNA
HIMS
MNKD